Near-infrared–conjugated humanized anti-carcinoembryonic antigen antibody targets colon cancer in an orthotopic nude mouse model

• Published in: The Journal of surgical research Vol. 218; pp. 139 - 143
• Main Authors: DeLong, Jonathan C., MD, Murakami, Takashi, MD, Yazaki, Paul J., PhD, Hoffman, Robert M., PhD, Bouvet, Michael, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2017
• Subjects: Animals; Antibodies, Monoclonal, Humanized; Carcinoembryonic Antigen - immunology; CEA; Colon cancer; Colonic Neoplasms - diagnostic imaging; Colonic Neoplasms - immunology; Female; Fluorescence; Fluorescent Dyes; HT29 Cells; Humans; Mice; Mice, Nude; Mouse models; Neoplasm Transplantation; Optical Imaging - methods; Orthotopic; Spectroscopy, Near-Infrared; Surgery; Fluorescence; Colon cancer; Orthotopic; Mouse models; CEA
• ISSN: 0022-4804; 1095-8673
• DOI: 10.1016/j.jss.2017.05.069

Abstract Background The success of a curative surgery for cancer is dependent on the complete removal of all cancer cells. Tumor visualization by the surgeon can be enhanced through fluorescent-antibody targeting. To further develop such technology, we selected humanized anti-carcinoembryonic antigen (CEA) conjugated to a near-infrared dye to target orthotopically implanted human colon cancer in nude mice. Materials and methods The HT-29 human colon cancer cell line was grown in culture and subcutaneously injected subcutaneously in mice. After 3 wk of growth, tumors were resected and cut into 2 mm3 fragments that were sutured to the cecum of five additional nude mice for orthotopic implantation. The tumors were allowed to grow for 4 wk at which point 3 had successful orthotopic tumor growth and were selected for injection of the humanized anti-CEA antibody conjugated to the near-infrared dye IRDye800CW (anti-CEA-IRDye800CW). The antibody-dye conjugate (75 μg) was administered via tail vein injection. Images were obtained with the Pearl Trilogy Small Animal Imaging System with both 700 and 800 nm channels and evaluated using Image Studio. Results Laparotomy was performed 24 h after labeling the tumors. When imaged through the 800 nm channel, the tumors were observed to be strongly labeled with anti-CEA-IRDye800. At 48 h, laparotomy was repeated which again demonstrated strong labeling of the tumors through the 800 nm channel, but with a lower absolute intensity (in relative units), than at 24 h for each of the three mice imaged. Conclusions Humanized anti-CEA-IRDye800CW can rapidly and effectively label CEA-expressing human colon cancer in an orthotopic nude mouse model. Given the ability of this technology to target and label tumors with great specificity, the anti-CEA-IRDye800CW is currently being developed for clinical use in fluorescence-guided surgery.